GenSight BIOLOGICS

A LEADING GENE THERAPY BIOTECHNOLOGY COMPANY

Corporate presentation

MAY 2025

GENSIGHT-BIOLOGICS.COM

Disclaimer

This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company"), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. They include all matters that are not historical facts. These forward-looking statements can be identified by the use of forward-looking terminology including the terms "developments", "estimates", "expects", "intends", "may", "milestones", "potential", "value", "time to market", "targeting", "on track", "planned", "will", "move to", or other variations or comparable terminology, or by discussions of strategy and funding, as well as the Company's, its subsidiaries' and affiliates' technology, and are based on financial and non-financial information, including projections as to the future regulatory situation and other information and assumptions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of the Company, its subsidiaries and affiliates or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company, its subsidiaries and affiliates disclaim any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard there to, or any events, or changes in conditions or circumstances on which any such statement, forecast or estimate is based.

This document is proprietary communication from GenSight Biologics S.A.

GenSight BIOLOGICS

The investment case for GenSight Biologics: Gene therapy company with promising candidate for pivotal trial

Late-stage biotech company focused on realizing the promise of gene therapy

Public company founded in 2012. Publicly listed on **Euronext Paris** (SIGHT)

Exclusive focus on developing and commercializing **gene therapies for neurodegenerative retinal diseases** and diseases of the central nervous system

Lead candidate with the potential to be the **first gene therapy** approved for a **mitochondrial disease**

Seasoned management team and supportive investor base to drive the strategy forward

Management team with **strong and highly relevant biotech experiences** in R&D and commercialization

Supportive base of healthcare specialist investors based in the EU and US

Last mile of clinical development for Phase III asset with unprecedented data in LHON*

Treatment of 252 patients (in clinical trials and real-world setting) showed **durable reversal of previously inevitable blindness**

Manufacturing process improved and **analytics methods upgraded** to address previous challenges

Continuing engagement with EMA, US FDA and UK MHRA to confirm registration pathway

No further clinical trial required for submission in the UK; restart of paid named access in France under review

Proof-of-concept in humans for cutting-edge optogenetic treatment in retinitis pigmentosa

Mutation-agnostic treatment for the leading inherited retinal disease

Patients who became blind decades before the trial **regained ability** to identify, locate and count objects**

*Leber Hereditary Optic Neuropathy. ***Nature Medicine* (May 2021).

A new chapter, led by a seasoned international management team …

Laurence Rodriguez

Chief Executive Officer

SANOFI (2011-2021)
GENZYME (2005-2011)
FRESENIUS (1998- 2005)
NUTRICIA/DANONE (1994-1998)

Magali Taiel

Chief Medical Officer

ProQR THERAPEUTICS (2016-2018)
ELI LILLY (2004-2016)
PFIZER (2001-2004)
SERVIER (1999-2001)
M.D., Board-certified ophthalmologist

Scott Jeffers

Chief Technical Officer

REDPIN THERAPEUTICS (2021-2022)
UNIQURE (2019-2021)
SELECTA BIOSCIENCES (2018-2019)
BRAMMER BIO (2015-2018)
Ph.D. in virology

Magali Gibou

Chief Regulatory & Quality Affairs Officer

SANGAMO THERAPEUTICS (2019-2023)
HOFFMANN LA ROCHE (2014-2019)
TRANSGENE (2007-2014)

Jan Eryk Umiastowski

Chief Financial Officer

BLUEBALLOON CAPITAL (2023-2024)
CEGEDIM (2007 -2023)
AMAS BANK (2005-2007)
JET FINANCES (2002-2005)

Julio Benedicto

SVP, Strategy & Operations

IMS/IQVIA (2012-2017)
BOOZ AND COMPANY (2011)
MONITOR DELOITTE (1994-2010)

Marion Ghibaudo

Chief Technical Medical Device Officer

MAUNA KEA TECHNOLOGIES (2018 – 2021)
L'OREAL (2009 – 2018)
Ph. D. in biophysics

… and overseen by a board of international industry experts as directors

Michael Wyzga

Chairman since March 2016

Corporate strategy

- Various senior positions at Genzyme Corporation
- Chairman: X4 Pharmaceuticals, Mereo Pharmaceuticals
- Board member: LogicBio, Adagiotherapeutics, Akebia therapeutics
- President of MSW Consulting Inc.

Prof. José-Alain Sahel

Director

Research and development

- Founding Chair, Vision Institute, Paris
- Distinguished Professor and Chair, Dept. of Ophthalmology, Univ. Of Pittsburgh
- Director, UPMC Vision Institute
- Winner, 2024 Wolf Prize in Medicine

Maritza McIntyre, Ph.D.

Independent Director

CMC and Regulatory Affairs

- 20 years of experience in development of biological molecule products in biotech firms and FDA
- Bavarian Nordic, REGENXBIO, Nanocor therapeutics, bamboo therapeutics
- President of Advanced Therapies Partners LLC

Simone Seiter, M.D., Ph.D.

Independent Director

Commercialization and launch excellence

- 30 years of experience in pharmaceutical Industry Simon Kucher and IQVIA
- Execution on global, regional and local level
- Board member: GenSight Biologics, Mediphage

Françoise de Craecker

Independent Director

Commercialization and operational excellence

- 40 years of experience in Pharmaceutical Industry
- Local, Regional and Global responsibilities
- Orphan Drugs in multiple Therapeutic Areas and Gene Therapies

Elsy Boglioli

Independent Director

Biotech scale-up and BD

- 15 years of experience in biotech industry
- Director at Womed, InPart, Metafora, FTI consulting
- Former COO Cellectis, Former Partner and MD at The Boston Consulting Group

Cedric Moreau

Representing Sofinnova Partners

Finance

- 18 years of experience in life sciences investment banking, 10 years of experience as a Healthcare equity analyst
- Managing director at ODDO BHF, Bryan Garnier

William Monteith

Independent Director

Manufacturing

- 43 years of experience in both small molecule and large molecule pharmaceutical manufacturing
- Program Director, North Carolina Life Sciences Biomanufacturing Forum

01

LUMEVOQ® in *ND4*-LHON

- Compelling data on treatment benefit and safety from treating 252 patients

LHON: rare mitochondrial disease with no effective options against acute and irreversible loss of vision

Natural history: acute, rapidly progressing and irreversible blindness

Evolution of vision from onset of disease



"The evolution of natural history eyes … shows an absence of recovery …"

Valerio Carelli et al.

Indirect Comparison of Lenadogene Nolparvovec Gene Therapy Versus Natural History in Patients with Leber Hereditary Optic Neuropathy Carrying the m.11778G>A MT-*ND4* Mutation. Ophthalmol Ther. https://doi.org/10.1007/s40123-022-00611-x

Devastating impact

- **Major cause of blindness** in young adults
- Vision loss caused by ***ND4*** (75% of cases[2]) mutation is the **most severe, with poorest prognosis**

ND4-LHON incidence	**800–1,000 new patients per year[1]**
Typical age of patient	**15–35 years old[2]**

Image source: illustrated from Newman NJ et al., Am J Ophthalmol. 141(6), 1061-1067,2006

1. Based on GenSight analysis of literature and health sector data.
2. Newman NJ, Carelli V, Taiel M, Yu-Wai-Man P. Visual Outcomes in Leber Hereditary Optic Neuropathy Patients With the m.11778G>A (MTND4) Mitochondrial DNA Mutation. *J Neuroophthalmol*. 2020;40(4):547-557.

LUMEVOQ®: enhanced AAV-based gene therapy to restore mitochondrial function and restore visual function

Exclusive MTS* technology to deliver gene therapy solution to damaged mitochondria

Conventional gene therapy mechanism ...

... Enhanced with MTS*





STEP 1

Vector containing wild-type mitochondrial gene delivered via intravitreal injection



STEP 2

Wild-type mitochondrial gene transcribed in the nucleus



STEP 3

Wild-type mRNA **delivered by MTS* directly** to mitochondrial surface, where protein synthesis occurs



STEP 4

Wild-type mitochondrial protein translocated inside the mitochondrion, where it **restores energy production**

*MTS: mitochondrial targeting sequence. Exclusive license.

Clinically meaningful and durable visual recovery, instead of inevitable blindness

Results consistent across 3 Phase III clinical trials (n=174) and early access/compassionate use programs (n=63)

REFLECT BILATERAL

PHASE III**

Mean improvement vs. vision nadir*, 5 years after one-time injection

ETDRS chart

BILATERAL INJECTION **Mean improvement vs. nadir*** *ETDRS letters*	
LUMEVOQ® eyes (1st eye)	**+19**
LUMEVOQ® eyes (2nd eye)	**+18**
48 patients vision loss ≤ 1 year	

Clinically meaningful = 15 or more letters

UNILATERAL INJECTION **Mean improvement vs. nadir*** *ETDRS letters*	
LUMEVOQ® eyes (1st eye)	**+20**
Placebo eyes	+14
50 patients vision loss ≤ 1 year	

REFLECT trial results = ~20 letters' improvement



Clinically meaningful = 15 or more letters

Clinically meaningful improvement of **Quality-of-Life** parameters

Note: Improvement in placebo eyes were due to a contralateral effect.

*"Nadir" defined as the **worst BCVA** from baseline to Year 5. Mean change from nadir: LOCF imputation for REFLECT.

**REFLECT is the third Phase III trial of LUMEVOQ®, along with RESCUE and REVERSE. REFLECT: NCT03293524. Database lock Dec. 31, 2024; manuscript in preparation. Topline results announced in February 2025 (https://www.gensight-biologics.com/2025/02/12/gensight-biologics-announces-five-year-efficacy-and-safety-results-for-lumevoq-gene-therapy-at-the-conclusion-of-the-reflect-study/).

For majority of patients, meaningful and durable visual recovery after one-time treatment with LUMEVOQ®

Results consistent across 3 Phase III clinical trials (n=174) and early access/compassionate use programs (n=63)

REFLECT BILATERAL

PHASE III**

Visual improvement vs. vision nadir*, 5 years after one-time injection

ETDRS chart



Clinically meaningful

BILATERAL INJECTION



48 patients
vision loss ≤ 1 year

UNILATERAL INJECTION
(placebo in non-treated eye)



50 patients
vision loss ≤ 1 year

REFLECT trial results = ~20 letters improvement

*"Nadir" defined as the **worst** **BCVA** from baseline to Year 5. Mean change from nadir: LOCF imputation for REFLECT.

**REFLECT is the third Phase III trial of LUMEVOQ®. REFLECT: NCT03293524. Database lock Dec. 31, 2024; manuscript in preparation. Topline results announced in February 2025 (https://www.gensight-biologics.com/2025/02/12/gensight-biologics-announces-five-year-efficacy-and-safety-results-for-lumevoq-gene-therapy-at-the-conclusion-of-the-reflect-study/).

Evidence from real life settings consistent with clinical trial data

Evolution of mean visual acuity over time (n = 63)



Vision function improvement at last available observation

(n=63 patients; 126 eyes)

Average change in visual acuity (vs. nadir)	**24 ETDRS letters IMPROVEMENT** > Conventional definition of meaningfulness
Improvement of at least 15 letters from nadir (%)	**63%**
% of eyes with on-chart vision	**61%**

All patients were treated with LUMEVOQ (63 patients; 126 eyes). Patients treated with idebenone were eligible for the early access program. At the date of data cutoff, 53 patients (106 eyes) had one year of complete data; 27 patients had 1.5 years of complete data; and 39 patients had 2 years of complete data.

Data cutoff: December 26, 2024

ARVO Conference 2025: Chiara La Morgia et al. Efficacy and Safety of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting

Highly favorable safety record

Comprehensive evidence from 252 patients treated in Phase I/II , four Phase III trials and early access

- **No study discontinuations** related to treatment or study procedure[1]
- **Excellent systemic tolerance**, related to the **limited biodissemination**[2]
- **Mostly mild** intraocular inflammation[3], **responsive to conventional treatment**, mostly corticosteroid eye drops alone
  - **REVERSE** and **RESCUE**: No protocol to prevent intraocular inflammation; no requirement for oral corticosteroids
  - **REFLECT**: Protocol to prevent intraocular inflammation with oral corticosteroids
- **Comparable favorable safety profile for unilateral and bilateral administration**

Notes:

1. No study discontinuation due to ocular adverse events (AEs); no ocular serious AEs (SAEs) in treated eyes (only 1 ocular SAE in a sham eye: retinal tear, unlikely related to treatment/procedure)
2. Negligible in the blood, not detected in the urine and limited and of short duration in the tears
3. The intraocular inflammation was considered likely to be related to the drug and occurred almost exclusively in the anterior chamber and the vitreous.

Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy. Catherine Vignal-Clermont et al. AJO 2022. https://doi.org/10.1016/j.ajo.2022.11.026
REVERSE: NCT02652780; RESCUE: NCT02652767; RESTORE: NCT03406104; REFLECT: NCT03293524.

Next for LUMEVOQ®: Bold Steps for Big Wins

- RECOVER trial
- Manufacturing
- Regulatory path

Why the RECOVER trial is required: gain full acceptance of clinical results by regulatory authorities in the US and EU

Unforeseen contralateral effect → inadequate control arm → requirement to demonstrate efficacy in new trial

- **Consistent contralateral effect** in Phase III trials: untreated eyes (sham or placebo) also experienced vision improvement
  - Animal and autopsy studies confirm biological basis (i.e., the contralateral effect is neither a placebo effect nor an artifact of the data)[1]
- Predefined efficacy test for the Phase III trials was based on the difference in visual improvement between treated eyes and untreated eyes

→ **Bilateral improvement** and better outcome for patients, but **predefined statistical test was not met**

- Regulatory authorities in the US and EU **were resistant to demonstration of efficacy based on indirect comparisons**, regardless of the statistical methodology[2]
  - Require **direct comparison** between patients randomized between an investigational arm and a prospectively defined control arm

Notes: 1. See next page. 2. Methodologies performed and discussed: indirect comparison of patient-level data; meta-analysis; match-adjusted indirect comparison.

The contralateral effect has underlying biological mechanisms

The design of the RECOVER trial needs to remove the confounding impact of the contralateral effect

Type of study	Finding	Reference
Animal (mice) 	**Transcription** of **LUMEVOQ ND4 DNA** in the contralateral untreated eyes	*McGrady Molecular Therapy 2023 https://doi.org/10.1016/j.ymthe.2023.03.035*
Animal (NHP) 	**Transfer** of **LUMEVOQ *ND4* DNA** from treated to untreated eyes	*Calkins J et al. Molecular Therapy 2021; Vol.23 : 307- 318 https://doi.org/10.1016/j.omtm.2021.09.013*
Human (autopsy) 	**Retinal transfection** of **LUMEVOQ *ND4*** in the contralateral untreated eye	*Abstract ARVO 2025: Carelli et al*

RECOVER Phase III trial: designed to succeed

Leverage insights and experience; incorporate regulatory feedback; engage top LHON clinical experts

Insights from previous trials:

- Optimal treatment window = **6 months to 1.5 years after onset**
- Magnitude of improvement and response rate
- Mean improvement plateaus after **1.5 years**
- Required sample size

GenSight trial experience and feasibility assessment:

- Collaboration with investigators, trial sites and patient groups
- Clinical trial timeline and management
- Budget management

RECOVER Phase III Trial

- 2-arm **global study** with a pure placebo arm and bilateral treatment arm
- Patients **6 mos.–1.5 yrs.** from onset of vision loss
- **Primary efficacy endpoint (at 1.5 years)** agreed with FDA and EMA
- **Designed** to optimize execution speed
- **Target initiation: early H2 2026**

Feedback from the FDA and EMA:

- Bilateral placebo injection in control arm
- Definition of the primary efficacy endpoint: visual acuity scale; choice of study eye
- Secondary endpoints
- Statistical methodology

Scientific Advisory Committee:

- Trial design
- Statistical plan
- Site selection
- Operational considerations
- Publication planning

Manufacturing: incorporating 2024 lessons into 2025 priorities



Last mile of clinical development: advancing towards marketing authorization

LUMEVOQ® regulatory path towards submission in key markets

U.S. FOOD & DRUG ADMINISTRATION

- **Scientific advice** received on new Phase III study RECOVER – positive feedback on overall design
- Further Phase III readiness interactions planned

EUROPEAN MEDICINES AGENCY

- **Scientific advice** received on new Phase III study RECOVER – positive feedback on overall design
- Further Phase III readiness interactions planned

MHRA
Regulating Medicines and Medical Devices

- Scientific advice meeting (December 2023) confirmed that **existing clinical data package (without RECOVER) can be submitted for review** in a marketing application

Initiation of RECOVER Phase III: Early H2 2026

Pre-submission meeting: Early H2 2026

Ongoing engagement with patient advocacy groups in Europe and the US

02

GS030

- Optogenetic treatment approach* for photoreceptor degenerative diseases with novel, mutation-agnostic mechanism of action
- Promising early results from PIONEER Phase I/II study show blind patients regaining ability to locate objects

*GS030 is a combination treatment consisting of a one-time gene therapy injection and a wearable medical device.

Optogenetics for Retinitis Pigmentosa

Retinitis Pigmentosa (RP)





- **Leading cause of inherited blindness:** 5-7% of newly diagnosed blindness in Wester countries
- Caused by mutations in **over 100 different genes** → photoreceptor degeneration leads to **severe visual disability by age 40-45**
- **No cure**; current interventions focus on **managing symptoms** rather than halting or reversing vision loss

GS030 Therapy: Bypass Degenerated Cells through Optogenetics

1. **Intravitreal** injection → RGC transfection
2. Expression of **light-sensitive** ChrimsonR on **bioengineered** RGC surface
3. Induction of neuronal signal by **photo-stimulating** RGCs



GS030 to date: favorable safety profile and promising early signals of reactivating visual function

Findings from PIONEER Phase I/II Clinical Trial

Safety

- **No study discontinuations** related to treatment or study procedure
- **Excellent systemic tolerance**, related to the **limited biodissemination**
- **Mild and moderate intraocular inflammation**, which was **responsive to conventional treatment**, mostly corticosteroid eye drops alone
  - No increased severity at high dose
  - Protocol to prevent intraocular inflammation using oral corticosteroids
- **Light stimulating goggles (ocular device) well-tolerated**

Efficacy signal (at one year)

- Vision improvement observed in some patients
  - **Before treatment:** barely able to perceive light
  - **One year after treatment**: ability to locate and count objects
- Best results at the highest dose

Results at one year released in Feb 2023

GenSight Biologics announces 1 Year safety data and efficacy signals from PIONEER Phase I/II clinical trial of GS030, an optogenetic treatment candidate for Retinitis Pigmentosa

Sahel, JA., Boulanger-Scemama, E., Pagot, C. et al. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med 27, 1223–1229 (2021). https://doi.org/10.1038/s41591-021-01351-4

03

Corporate & Finance

GenSight Biologics Listed in EuroNext Paris

Company Overview

Headquarter:	Paris, France
Listing:	Euronext Paris
Tickers:	SIGHT
ISIN:	FR0013183985
Market Cap: (May. 19, 2025)	€27m
Cash Position: (Mar. 31, 2025)	€0.9m*
Cash runway:	Mid-June 2025
Outstanding Shares: (Apr.16, 2025)	131.2m
Latest Equity Raised: (Mar.7, 2025)	€0.9m
Equity raised to date: (Dec. 31, 2024)	€223m
IPO Date:	July 13, 2016

Shareholder Structure, as of Apr.16, 2025



Analyst Coverage

CHARDAN
Daniil Gataulin
(US)

ODDO BHF
Martial Descoutures
(FR)

Kepler Cheuvreux
Justine Telliez
(FR)

* As of May 19, the Company has received confirmation that €0.7 million of its Research Tax Credit (CIR) will be received shortly, with the remaining €0.4 million to be paid in July 2025.

Backup

Clinically meaningful and durable visual recovery, instead of inevitable blindness

Mean Improvement vs. vision nadir*, 5 years after one-time injection

BILATERAL INJECTION		Unilateral Injection	Unilateral Injection	Unilateral Injection
Mean improvement vs. nadir* in ETDRS letters		**Mean improvement vs. nadir* in ETDRS lettes**	**Mean improvement vs. nadir* in ETDRS letters**	**Mean improvement vs. nadir* in ETDRS letters**
LUMEVOQ® eyes (1st eye)	**+19**	LUMEVOQ® eyes **+20**	LUMEVOQ® eyes **+22**	LUMEVOQ® eyes **+23**
LUMEVOQ® eyes (2nd eye)	**+18**	Placebo eyes +14	Sham eyes +20	Sham eyes +18
48 patients vision loss ≤ 1 year		**50 patients** vision loss ≤ 1 year	**37 patients** vision loss 6 - 12 months	**39 patients** vision loss ≤ 6 months

Clinically meaningful: ≥15 letters

Note: Improvement in placebo and sham eyes were due to a contralateral effect.

Clinically meaningful improvement of **Quality-of-Life** parameters

*"Nadir" defined as the **worst BCVA** from baseline to time point of interest (5 years for REVERSE and RESCUE, 4 years for REFLECT). Mean change from nadir: last observation for REVERSE/RESTORE and RESCUE/RESTORE (Database lock RESTORE: Jul 4, 2022, completed studies); LOCF imputation for REFLECT (data cut-off Feb 20, 2024, study ongoing). REVERSE: NCT02652780; RESCUE: NCT02652767; RESTORE: NCT03406104; REFLECT: NCT03293524. Data on file; manuscripts in publication review

Majority of patients experience meaningful, durable visual recovery after one-time treatment with LUMEVOQ

REFLECT Trial @ 5 Years
(injected ≤12 months after onset)

REVERSE+RESTORE Trial @ 5 Years
(injected 6–12 months after onset)

RESCUE+RESTORE Trial @ 5 Years
(up to 6 months after onset)

Improvement after BILATERAL injection



69% of patients
At least 15-letter improvement

Improvement after unilateral injection
(placebo)



Improvement after unilateral injection
(sham)



Improvement after unilateral injection
(sham)



Average visual recovery from nadir is **clinically meaningful (≥15-letter improvement)**

Majority of patients experienced at least 15-letter (clinically meaningful) improvement in visual acuity relative to their vision nadir

*For REFLECT, mean improvement shown is that for 1st injected eyes.